Table 3 Cost-effectiveness of adding the MVA85A vaccine to the BCG vaccine, in 2012 USD
Strategy | 10-year costs | Absolute number of TB cases | Absolute number of TB deaths | ICER per TB case averted (USD 2012) | ICER per TB deaths averted (USD 2012) |
|---|---|---|---|---|---|
| Â | (USD 2012) | Â | Â | Â | Â |
Discounted (3%) | Â | Â | Â | Â | Â |
BCG alone | 84.17 | 0.09101 | 0.0003501817 | Â | Â |
plus MVA85A | 98.23 | 0.07828 | 0.0003006626 | 1,105 | 284,017 |
Undiscounted | Â | Â | Â | Â | Â |
BCG alone | 97.65 | 0.10627 | 0.0004174069 | Â | Â |
plus MVA85A | 109.80 | 0.09138 | 0.0003583168 | 816 | 205,603 |
Discounted (6%) | Â | Â | Â | Â | Â |
BCG alone | 73.53 | 0.07885 | 0.0002969804 | Â | Â |
plus MVA85A | 89.10 | 0.06785 | 0.0002550313 | 1,416 | 371,271 |